# RD Saúde Profit Hits R$362 Million in 4Q25 as Digital Sales Surge

*Retail pharmacy giant posts strong revenue growth and market-share gains as GLP-1 drugs and omnichannel sales boost performance.*

- Published: 2026-03-03
- Updated: 2026-03-04
- Section: Insights
- Tags: Brazil pharmacy market, digital pharmacy Brazil, GLP-1 drugs Brazil, RADL3, Raia Drogasil results, rd saúde, RD Saúde earnings
- URL: https://brazilstockguide.com/insights/rd-saude-profit-hits-r362-million-in-4q25-as-digital-sales-surge/

![RD, Raia Drogasil, Pharmacy](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/11/RD-Raia-Drogasil-Pharmacy.png?fit=1024%2C683&ssl=1)

**By Brazil Stock Guide –** RD Saúde (B3: RADL3), the parent company of the Raia and Drogasil pharmacy chains, reported **adjusted net income of R$362 million in the fourth quarter of 2025**, as strong demand for prescription drugs and rapid growth in digital channels accelerated the company’s sales momentum.

Gross revenue reached **R$13.0 billion in the quarter**, up **19.8% year over year**, while adjusted EBITDA totaled **R$936 million**, rising **38.2%**, with a margin of **7.2%**. For the full year, the company posted **R$47.6 billion in revenue**, an increase of **13.9%**, and **adjusted net income of R$1.34 billion**.

The results mark a rebound after a challenging start to 2025, when intensified competition and operational pressures weighed on margins. Management implemented a series of operational adjustments — including price repositioning, store-level staffing increases and tighter cost discipline — helping restore sales momentum during the second half of the year.

**GLP-1 Drives Prescription Growth**

A key driver of growth was the rapid expansion of **GLP-1 medications**, widely used for diabetes and increasingly prescribed for weight loss. The category reached **double-digit participation in retail sales during the fourth quarter**, boosting prescription drug revenue.

Executives expect the market to expand further as new therapies are launched and as **patents for semaglutide-based drugs approach expiration in 2026**, potentially allowing lower-priced alternatives to enter the market and broaden access.

RD Saúde believes its nationwide logistics network and store footprint position the company to capture an outsized share of that growth.

**Digital Becomes Strategic Engine**

Digital commerce continues to transform the company’s business model. Online sales reached **R$11.3 billion in 2025**, representing **59% growth year over year**, while digital penetration climbed to **29.3% of retail sales in the fourth quarter**.

Mobile apps have become the dominant channel, accounting for more than **80% of digital transactions**, while rapid delivery and “buy-online-pick-up-in-store” services have strengthened customer engagement.

Management said the integration between physical stores and digital channels — with most online orders fulfilled directly from nearby pharmacies — has become a structural competitive advantage.

**Expansion and Market Share Gains**

RD Saúde ended the year with **3,547 pharmacies across Brazil**, after opening **330 new stores in 2025**. The company plans to maintain a similar expansion pace in 2026, targeting **330 to 350 new units**.

The strategy has helped the retailer expand its national market share to **19.5%**, a gain of **1.7 percentage points year over year**, with growth across all regions.

Sales at mature stores — locations operating for more than three years — grew **14.5% in the fourth quarter**, significantly outperforming Brazil’s official annual drug price adjustment.

**Portfolio Shift After 4Bio Sale**

Alongside its earnings release, RD Saúde announced the **sale of its specialty-drug subsidiary 4Bio** to a company linked to the Profarma group, reflecting a broader effort to focus capital allocation on the core pharmacy retail business.

The transaction has a base value of about **R$600 million**, with total proceeds potentially reaching **around R$700 million over five years**, including financial adjustments.

Management said the divestment should strengthen the company’s balance sheet and allow greater investment in store expansion, digital capabilities and high-growth health categories.

Looking ahead to 2026, RD Saúde plans to deepen its focus on recurring customer relationships, expand health services inside pharmacies and reinforce leadership in high-growth segments such as weight-loss treatments, beauty and wellness.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/rd-saude-profit-hits-r362-million-in-4q25-as-digital-sales-surge/
